Joel Greenblatt's ABT Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 113,177 shares of Abbott Laboratories (ABT) worth $14.18 M, representing 0.05% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2016, adding 1.01 M shares. Largest reduction occurred in Q4 2015, reducing 1.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +48,589 | Add 75.23% | 113,177 | $125.29 |
| Q3 2025 | -13,842 | Reduce 17.65% | 64,588 | $133.94 |
| Q2 2025 | +22,316 | Add 39.77% | 78,430 | $136.01 |
| Q1 2025 | +16,779 | Add 42.66% | 56,114 | $132.65 |
| Q4 2024 | -969 | Reduce 2.40% | 39,335 | $113.11 |
| Q3 2024 | +5,573 | Add 16.05% | 40,304 | $114.01 |
| Q2 2024 | +326 | Add 0.95% | 34,731 | $103.91 |
| Q1 2024 | +3,493 | Add 11.30% | 34,405 | $113.66 |
| Q4 2023 | -577 | Reduce 1.83% | 30,912 | $110.07 |
| Q3 2023 | -3,989 | Reduce 11.24% | 31,489 | $96.85 |
| Q2 2023 | -30,060 | Reduce 45.87% | 35,478 | $109.02 |
| Q1 2023 | -23,528 | Reduce 26.42% | 65,538 | $101.26 |
| Q4 2022 | -13,799 | Reduce 13.41% | 89,066 | $109.79 |
| Q3 2022 | -12,293 | Reduce 10.67% | 102,865 | $96.76 |
| Q2 2022 | +4,349 | Add 3.92% | 115,158 | $108.65 |
| Q1 2022 | +51,671 | Add 87.37% | 110,809 | $118.36 |
| Q4 2021 | -5,107 | Reduce 7.95% | 59,138 | $140.74 |
| Q3 2021 | +7,880 | Add 13.98% | 64,245 | $118.13 |
| Q2 2021 | +998 | Add 1.80% | 56,365 | $115.92 |
| Q1 2021 | +6,741 | Add 13.86% | 55,367 | $119.84 |
| Q4 2020 | -27,304 | Reduce 35.96% | 48,626 | $109.49 |
| Q3 2020 | -18,170 | Reduce 19.31% | 75,930 | $108.82 |
| Q2 2020 | +23,364 | Add 33.03% | 94,100 | $91.43 |
| Q1 2020 | +60,775 | Add 610.13% | 70,736 | $78.91 |
| Q4 2019 | +2,643 | Add 36.12% | 9,961 | $86.84 |
| Q3 2019 | -3,018 | Reduce 29.20% | 7,318 | $83.63 |
| Q2 2019 | -197,960 | Reduce 95.04% | 10,336 | $84.08 |
| Q1 2019 | +48,020 | Add 29.96% | 208,296 | $79.94 |
| Q4 2018 | +23,405 | Add 17.10% | 160,276 | $72.33 |
| Q3 2018 | -31,204 | Reduce 18.57% | 136,871 | $73.36 |
| Q2 2018 | -432,564 | Reduce 72.02% | 168,075 | $60.99 |
| Q1 2018 | -256,844 | Reduce 29.95% | 600,639 | $59.92 |
| Q4 2017 | +839,632 | Add 4703.56% | 857,483 | $57.07 |
| Q3 2017 | +17,851 | New Buy | 17,851 | $53.39 |
| Q2 2017 | -399,925 | Sold Out | 0 | $0.00 |
| Q1 2017 | -610,673 | Reduce 60.43% | 399,925 | $44.41 |
| Q4 2016 | +1.01 M | New Buy | 1.01 M | $38.41 |
| Q3 2016 | -130,054 | Sold Out | 0 | $0.00 |
| Q2 2016 | -731,808 | Reduce 84.91% | 130,054 | $39.31 |
| Q1 2016 | +763,024 | Add 771.99% | 861,862 | $41.83 |
| Q4 2015 | -1.36 M | Reduce 93.21% | 98,838 | $44.91 |
| Q3 2015 | +411,996 | Add 39.49% | 1.46 M | $40.22 |
| Q2 2015 | +1 M | Add 2409.54% | 1.04 M | $49.08 |
| Q1 2015 | +41,573 | New Buy | 41,573 | $46.33 |
Joel Greenblatt's Abbott Laboratories Investment FAQs
Joel Greenblatt first purchased Abbott Laboratories (ABT) in Q1 2015, acquiring 41,573 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Abbott Laboratories (ABT) for 44 quarters since Q1 2015.
Joel Greenblatt's largest addition to Abbott Laboratories (ABT) was in Q4 2016, adding 1,010,598 shares worth $38.82 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 113,177 shares of Abbott Laboratories (ABT), valued at approximately $14.18 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 0.05% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Abbott Laboratories (ABT) was 1,455,289 shares, as reported at the end of Q3 2015.